GSK takes option to develop T-cell therapy with Adaptimmune – pharmaphorum
pharmaphorum |
GSK takes option to develop T–cell therapy with Adaptimmune
pharmaphorum Novartis just got the first chimeric antigen receptor T–cell (CAR-T) therapy approved in the US, and Gilead has swooped with a $12 billion bid to acquire Kite Pharma, which has a rival T–cell therapy under review in the US and Europe. Adaptimmune will … GSK wants in on Adaptimmune’s Adaptable T cell Cancer TreatmentLabiotech.eu (blog) |
Health24 |
South Africa’s ‘Bubble Boy’ receives gene therapy in the US
Health24 At this meeting she asked about gene therapy because the transplant process came with many risks. “Gene therapy was showing great promise the UK, France, Italy and America for children battling immune deficiencies and who lacked a matched donor.”. |
News-Medical.net |
CGT Catapult partners with TrakCel to incorporate tracking technology into cell and gene therapy manufacturing centre
News-Medical.net The Cell and Gene Therapy Catapult (CGT Catapult) today announces a partnership agreement with UK-headquartered company TrakCel to incorporate its needle-to-needle supply chain management platform into the CGT Catapult’s large-scale cell and … |
Edgy Labs (blog) |
Human embryo editing won’t lead to ‘designer babies’ – USA Today
USA TODAY The recent news that scientists have successfully edited a human embryo to fix a potentially lethal heart defect is an exciting medical and biotechnological … The Latest Guide to Understanding CRISPR-Cas9 – Edgy LabsEdgy Labs (blog) |
The Korea Herald |
Stem Cell: Tied Up In Knots
BW Businessworld Dr Firuza Parikh was one of the most discussed names in the media in India in the early 2000. Considered the face of India’s stem cell research then, Parikh was the founder- director of Mukesh Ambani-promoted Reliance Life Sciences. Speaking at one of … [Weekender] Secret to reversing aging? Think againThe Korea Herald North America Stem Cell Market by 2022: Leading Countries, Consumption, Drivers, Trends, Challenges, Revenue …satPRnews (press release) |
|
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
Markets Insider He continued, “We view the Replimune management team as the most experienced in the oncolytic immunotherapy field, having developed the first and only oncolytic product to obtain approval by the FDA.” Replimune also separately announced today the … Replimune Appoints Howard L. Kaufman, MD, FACS as Chief Medical OfficerPR Newswire (press release) |
|
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
Markets Insider He continued, “We view the Replimune management team as the most experienced in the oncolytic immunotherapy field, having developed the first and only oncolytic product to obtain approval by the FDA.” Replimune also separately announced today the … Replimune Appoints Howard L. Kaufman, MD, FACS as Chief Medical OfficerPR Newswire (press release) |